Zoekresultaten - Sridharan Gururangan

Verfijn jouw resultaten
  1. 1
    Social Functioning and Facial Expression Recognition in Survivors of Pediatric Brain Tumors

    Social Functioning and Facial Expression Recognition in Survivors of Pediatric Brain Tumors door Melanie J. Bonner, Kristina K. Hardy, Victoria W. Willard, Kelly K. Anthony, M. Hood, Sridharan Gururangan

    Gepubliceerd in 2008
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    Intracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration

    Intracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration door Jessica Cohen‐Pfeffer, Sridharan Gururangan, Thomas Lester, Daniel A. Lim, Adam J. Shaywitz, Manfred Westphal, Irene Slavc

    Gepubliceerd in 2016
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    Best practices for the use of intracerebroventricular drug delivery devices

    Best practices for the use of intracerebroventricular drug delivery devices door Irene Slavc, Jessica Cohen‐Pfeffer, Sridharan Gururangan, Jeanne Krauser, Daniel A. Lim, Marcos Vinícius Calfat Maldaun, Christoph Schwering, Adam J. Shaywitz, Manfred Westphal

    Gepubliceerd in 2018
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

    Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma door David A. Reardon, James J. Vredenburgh, April Coan, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, Sith Sathornsumetee, Jeremy N. Rich, James E. Herndon, Henry S. Friedman

    Gepubliceerd in 2011
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  5. 5
    Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

    Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma door David A. Reardon, Merrill J. Egorin, Annick Desjardins, James J. Vredenburgh, Jan H. Beumer, Theodore Lagattuta, Sridharan Gururangan, James E. Herndon, August J. Salvado, Henry S. Friedman

    Gepubliceerd in 2009
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  6. 6
    Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

    Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma door David A. Reardon, Jennifer A. Quinn, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, Michael Badruddoja, James E. Herndon, Jeannette M. Dowell, Allan H. Friedman, Henry S. Friedman

    Gepubliceerd in 2004
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  7. 7
    Short-Term Efficacy of Methylphenidate: A Randomized, Double-Blind, Placebo-Controlled Trial Among Survivors of Childhood Cancer

    Short-Term Efficacy of Methylphenidate: A Randomized, Double-Blind, Placebo-Controlled Trial Among Survivors of Childhood Cancer door Raymond K. Mulhern, Raja B. Khan, Stuart L. Kaplan, Susan Helton, Robbin Christensen, Melanie J. Bonner, Ronald T. Brown, Xiaoping Xiong, Sengjie Wu, Sridharan Gururangan, Wilburn E. Reddick

    Gepubliceerd in 2004
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  8. 8
    Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study

    Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study door Sridharan Gururangan, Susan Chi, Tina Young Poussaint, Arzu Onar‐Thomas, Richard J. Gilbertson, Sridhar Vajapeyam, Henry S. Friedman, Roger J. Packer, Brian Rood, James M. Boyett, Larry E. Kun

    Gepubliceerd in 2010
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  9. 9
    Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

    Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma door David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, James E. Herndon, Jennifer Marcello, J. Norfleet, Roger E. McLendon, John H. Sampson, Henry S. Friedman

    Gepubliceerd in 2009
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  10. 10
    Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience

    Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience door Christopher D. Turner, Sridharan Gururangan, James D. Eastwood, Krystal S. Bottom, Melody Watral, Rodney Beason, Roger E. McLendon, Allan H. Friedman, Sandra Tourt-Uhlig, Langdon L. Miller, Henry S. Friedman

    Gepubliceerd in 2002
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  11. 11
    Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

    Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma door David A. Reardon, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, Anuradha Bulusu, Stevie Threatt, Allan H. Friedman, James J. Vredenburgh, Henry S. Friedman

    Gepubliceerd in 2011
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  12. 12
    Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

    Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy door David A. Reardon, Annick Desjardins, Katherine B. Peters, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, April Coan, Stevie Threatt, Allan H. Friedman, Henry S. Friedman

    Gepubliceerd in 2011
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  13. 13
    Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

    Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma door Sith Sathornsumetee, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, Jennifer Marcello, James E. Herndon, Alyssa Mathe, Marta Hamilton, Jeremy N. Rich, J. Norfleet, Sridharan Gururangan, Henry S. Friedman, David A. Reardon

    Gepubliceerd in 2010
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  14. 14
    Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

    Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study door David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Sith Sathornsumetee, Roger E. McLendon, James E. Herndon, Jennifer Marcello, J. Norfleet, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman

    Gepubliceerd in 2009
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  15. 15
    Phase I Trial of Single-Dose Temozolomide and Continuous Administration of <i>O</i>6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report

    Phase I Trial of Single-Dose Temozolomide and Continuous Administration of <i>O</i>6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report door Alberto Broniscer, Sridharan Gururangan, Tobey J. MacDonald, Stewart Goldman, Roger J. Packer, Clinton F. Stewart, Dana Wallace, Mary K. Danks, Henry S. Friedman, Tina Young Poussaint, Larry E. Kun, James M. Boyett, Amar Gajjar

    Gepubliceerd in 2007
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  16. 16
    Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

    Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma door James J. Vredenburgh, Annick Desjardins, James E. Herndon, Jeannette M. Dowell, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, Melissa Wagner, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman

    Gepubliceerd in 2007
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  17. 17
    Temozolomide in Children with progressive low-grade glioma1

    Temozolomide in Children with progressive low-grade glioma1 door Sridharan Gururangan, Michael J. Fisher, Jeffrey C. Allen, James E. Herndon, Jennifer A. Quinn, David A. Reardon, James J. Vredenburgh, Annick Desjardins, Peter C. Phillips∥, Melody Watral, Jeanne Krauser, Allan H. Friedman, Henry S. Friedman

    Gepubliceerd in 2007
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  18. 18
    Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

    Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy door David A. Reardon, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Jeremy N. Rich, Roger E. McLendon, James E. Herndon, Jennifer Marcello, Stevie Threatt, Allan H. Friedman, James J. Vredenburgh, Henry S. Friedman

    Gepubliceerd in 2010
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  19. 19
    Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

    Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma door David A. Reardon, James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Jennifer Marcello, James E. Herndon, Roger E. McLendon, Dorothea Janney, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman

    Gepubliceerd in 2010
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  20. 20
    Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma

    Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma door Sridharan Gururangan, Jeanne Krauser, Melody Watral, Tim Driscoll, Nicole Larrier, David A. Reardon, Jeremy N. Rich, Jennifer A. Quinn, James J. Vredenburgh, Annick Desjardins, Roger E. McLendon, Herbert E. Fuchs, Joanne Kurtzberg, Henry S. Friedman

    Gepubliceerd in 2008
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: